Abstract Piperacillin-tazobactam (PIP-TAZ) is commonly used to treat intraabdominal
infections; however, its penetration into abdominal sites is unclear. A pharmacokinetic …

The aim of this study was to develop a population pharmacokinetic model for piperacillin
(PIPC)/tazobactam (TAZ) in late elderly patients with pneumonia and to optimize the …

Little is known of the effects of obesity on ertapenem drug disposition and
pharmacodynamics. Thirty healthy volunteers in three body mass index (BMI) groups (10 per …

Severe sepsis and septic shock can alter the pharmacokinetics of broad-spectrum β-lactams
(meropenem, ceftazidime/cefepime, and piperacillin-tazobactam), resulting in inappropriate …

Purpose The aim of the study was to investigate the in vitro antiinfective effect of piperacillin-
tazobactam (PIP-TZB) combinations on Escherichia coli in simulations of free concentration …

Optimal dosing of β-lactam antibiotics in critically ill patients is a challenge given the
unpredictable pharmacokinetic profile of this patient population. Several studies have shown …

Piperacillin in combination with tazobactam, a β-lactamase inhibitor, is a commonly used
intravenous antibiotic for the empirical treatment of infection in intensive care patients …

Objectives: To characterize the population pharmacokinetics of piperacillin and tazobactam
in critically ill infants and children, in order to develop an evidence-based dosing regimen …

Methods: Blood samples (2–4 per child) were collected from 13 children ages 9 months to 6
years admitted to the pediatric intensive care unit who were receiving standard piperacillin …

Study Objective To evaluate the pharmacokinetic and pharmacodynamic profiles of
piperacillin‐tazobactam administered as a 4‐hour infusion in critically ill patients undergoing …